HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA's Dietary Supplement Programs Deserve A Raise, Trade Groups Tell Senate Appropriators

Executive Summary

Compliant industry drove US market growth to $55bn in 2020, and faster growth and higher sales are ahead if FDA’s Office of Dietary Supplement Programs has sufficient funding to eliminate non-compliant businesses.

You may also be interested in...



FDA Food Programs Chief Assured On Supplement Office Move, Pessimistic On Agency Budget

“We think that this structure actually provides us the best path forward in terms of optimizing on our resources,” Jim Jones says of ODSP move. On the other hand, he says Congress didn’t appropriate for the agency’s optimal operation.

US FDA’s First Deputy Commissioner For Foods Studied For Post In Agency’s External Review

James Jones had 30-year career at the EPA before participating in the Reagan-Udall Foundation’s review of FDA’s food safety programs, reaching deep into agency’s current structural and operational norms to suggest far-reaching changes.

US FDA’s Planned NDIN Guidance On Master Files Not Worth Paper It Would Be Written On – CRN

FDA needs additional funding to support the work of enforcing recommendations from NDIN guidances on separate sections of requirements, particularly for planned guidance on supplement master file framework, CRN head Steve Mister tells Office of Dietary Supplement Programs.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS151404

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel